1
|
García E, Gil P, Miñambres I, Benitez-Amaro A, Rodríguez C, Claudi L, Julve J, Benitez S, Sánchez-Quesada JL, Rives J, Garcia-Moll X, Vilades D, Perez A, Llorente-Cortes V. Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control. Front Endocrinol (Lausanne) 2023; 14:1236487. [PMID: 37635956 PMCID: PMC10450024 DOI: 10.3389/fendo.2023.1236487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Accepted: 07/20/2023] [Indexed: 08/29/2023] Open
Abstract
Background Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism. Objectives To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization. Methods This single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c > 8.5%), and 12 healthy control, age- and sex-matched volunteers. sLRP1 and ANP levels were measured by immunoassays at T2DM onset and at one year after optimization of glycemic control (HbA1c ≤ 6.5%). Results T2DM had higher sLRP1 levels than the control group (p = 0.014) and lower ANP levels (p =0.002). At 12 months, 23 T2DM patients reached the target of HbA1c ≤ 6.5%. These patients significantly reduced sLRP1 and increased ANP levels. Patients who did not achieve HbA1c < 6.5% failed to normalize sLRP1 and ANP levels. There was an inverse correlation in the changes in sLRP1 and ANP (p = 0.031). The extent of sLRP1 changes over 12 months of metabolic control positively correlated with those of total cholesterol, LDL cholesterol, TG, TG/HDLc, and apolipoprotein B. Conclusions Newly diagnosed T2DM patients have an increased sLRP1/ANP ratio, and increased sLRP1 and decreased ANP levels are normalized in the T2DM patients that reached an strict glycemic and metabolic control. sLRP1/ANP ratio could be a reliable marker of cardiometabolic function.
Collapse
Affiliation(s)
- Eduardo García
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Pedro Gil
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
| | - Inka Miñambres
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
| | - Aleyda Benitez-Amaro
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
| | - Claudia Rodríguez
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
| | - Lene Claudi
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
| | - Josep Julve
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Sonia Benitez
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Jose Luís Sánchez-Quesada
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Jose Rives
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
| | - Xavier Garcia-Moll
- Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
| | - David Vilades
- Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
- Cardiac Imaging Unit, Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain
| | - Antonio Perez
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Vicenta Llorente-Cortes
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|